Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
May 24, 2024 09:20 ET
|
Renovaro Inc
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
Decklar Granted Management Cease Trade Order and Provides Bi-Weekly Default Status Report
May 24, 2024 09:02 ET
|
Decklar Resources Inc.
CALGARY, Alberta, May 24, 2024 (GLOBE NEWSWIRE) -- Decklar Resources Inc. (TSX-V: DKL) (OTC: DKLRF) (FSE: A1U1) (the “Company” or “Decklar”) is providing this bi-weekly default status report in...
EnWave Reports 2024 Second Quarter Consolidated Interim Financial Results
May 24, 2024 09:00 ET
|
EnWave Corporation
VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) today reported the Company’s consolidated interim financial...
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the...
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
May 24, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
May 24, 2024 08:00 ET
|
Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced...
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
BULGOLD Announces Filing of First Quarter Financial Results for Three Months Ended March 31, 2024
May 24, 2024 07:30 ET
|
BULGOLD Inc.
TORONTO, May 24, 2024 (GLOBE NEWSWIRE) -- BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce that it has filed its unaudited condensed interim financial statements and...
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024 18:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies...
Premier Health Reports 2024 Second Quarter Results
May 23, 2024 17:30 ET
|
Premier Health of America Inc.
MONTRÉAL, May 23, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly...